<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36052466</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>08</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae.</ArticleTitle><Pagination><StartPage>e487</StartPage><EndPage>e490</EndPage><MedlinePgn>e487-e490</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciac722</ELocationID><Abstract><AbstractText>The diagnosis of postacute sequelae of coronavirus disease 2019 (PASC) poses an ongoing medical challenge. To identify biomarkers associated with PASC we analyzed plasma samples collected from PASC and coronavirus disease 2019 patients to quantify viral antigens and inflammatory markers. We detect severe acute respiratory syndrome coronavirus 2 spike predominantly in PASC patients up to 12 months after diagnosis.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Swank</LastName><ForeName>Zoe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senussi</LastName><ForeName>Yasmeen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manickas-Hill</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Xu G</ForeName><Initials>XG</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jonathan Z</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alter</LastName><ForeName>Galit</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walt</LastName><ForeName>David R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-5524-7348</Identifier><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>NIH</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Hum Cell. 2023 Jan;36(1):483-485. doi: 10.1007/s13577-022-00809-y</RefSource><PMID Version="1">36214989</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="Y">Antigens, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 antigens</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of COVID-19 (PASC)</Keyword><Keyword MajorTopicYN="N">spike</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. D. W. has a financial interest in Quanterix Corporation, a company that develops an ultra-sensitive digital immunoassay platform. He is an inventor of the single molecule array technology, a founder of the company and also serves on its Board of Directors. D. W.'s interests were reviewed and are managed by Brigham and Women's Hospital and Partners Healthcare in accordance with their conflict of interest policies. He also holds stock and stock options for Quanterix Corporation. G. A. reports grants or contracts from Biontech, Merck, and BMS; consulting fees from Sanofi and Moderna, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from GSK and Astrazeneca; patents from REFORM&#x2014;Antibody Engineering&#x2014;MGH; CAPRISA CAP276 HIV monoclonal DSMB; is a part of the Sanofi Scientific Advisory Board; and holds stock or stock options for Systems Seromyx and Leyden Labs. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>2</Day><Hour>3</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36052466</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId><ArticleId IdType="pii">6686531</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med 2021; 27:601&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization (WHO) . In the wake of the pandemic: preparing for Long COVID. 2021. Available at: https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/publications-and-technical-guidance/2021/in-the-wake-of-the-pandemic-preparing-for-long-covid-2021. Accessed 11 May 2022</Citation></Reference><Reference><Citation>Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends Immunol 2022; 43:268&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesh R, Grach SL, Ghosh AK, et al. . The female-predominant persistent immune dysregulation of the post-COVID syndrome. Mayo Clin Proc 2022; 97:454&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8817110</ArticleId><ArticleId IdType="pubmed">35135695</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata AF, Maley AM, Wu C, et al. . Ultra-sensitive serial profiling of SARS-CoV-2 antigens and antibodies in plasma to understand disease progression in COVID-19 patients with severe disease. Clin Chem 2020; 66:1562&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499543</ArticleId><ArticleId IdType="pubmed">32897389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata AF, Cheng CA, Desjardins M, et al. . Circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients. Clin Infect Dis 2022; 74:715&#x2013;8. 10.1093/cid/ciab465</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab465</ArticleId><ArticleId IdType="pmc">PMC8241425</ArticleId><ArticleId IdType="pubmed">34015087</ArticleId></ArticleIdList></Reference><Reference><Citation>Chertow D, Stein S, Ramelli A, et al. . SARS-CoV-2 infection and persistence throughout the human body and brain. Published online December 20, 2021. 10.21203/rs.3.rs-1139035/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1139035/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonker LM, Gilboa T, Ogata AF, et al. . Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J Clin Invest. Published online May 2021; 131. 10.1172/JCI149633</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI149633</ArticleId><ArticleId IdType="pmc">PMC8279585</ArticleId><ArticleId IdType="pubmed">34032635</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, et al. . Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med 2022; 3:371&#x2013;387.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Troyer Z, Alhusaini N, Tabler CO, et al. . Extracellular vesicles carry SARS-CoV-2 spike protein and serve as decoys for neutralizing antibodies. J Extracell Vesicles 2021; 10:e12112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8213968</ArticleId><ArticleId IdType="pubmed">34188786</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng MH, Zhang S, Porritt RA, et al. . Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Proc Natl Acad Sci 2020; 117:25254&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7568239</ArticleId><ArticleId IdType="pubmed">32989130</ArticleId></ArticleIdList></Reference><Reference><Citation>Avolio E, Carrabba M, Milligan R, et al. . The SARS-CoV-2 spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease. Clin Sci 2021; 135:2667&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8674568</ArticleId><ArticleId IdType="pubmed">34807265</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Y, Zhang J, Schiavon CR, et al. . SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res 2021; 128:1323&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8091897</ArticleId><ArticleId IdType="pubmed">33784827</ArticleId></ArticleIdList></Reference><Reference><Citation>DeOre BJ, Tran KA, Andrews AM, Ramirez SH, Galie PA. SARS-CoV-2 spike protein disrupts blood&#x2013;brain barrier integrity via RhoA activation. J Neuroimmune Pharmacol 2021; 16:722&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8536479</ArticleId><ArticleId IdType="pubmed">34687399</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, et al. . Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis 2021; 224:1839&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol 2022; 23:210&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>